Johnson & Johnson (J&J) managed to beat analyst earnings estimates due to unexpectedly strong first-quarter results in its consumer health and pharmaceutical businesses. But while those saw revenues climb in the double digits, its medical devices business declined by almost 5% due to deferred procedures. Wall Street rewarded the New Brunswick, N.J.-based company by driving its shares (NYSE:JNJ) up more than 5%. That’s even though the company also lowered its 2020 guidance.
Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting.
The newest angle in the partnership between Johnson & Johnson and the U.S. federal government, part of the company’s $1 billion commitment to COVID-19 R&D, is designed to drive its lead candidate into the clinic by year-end and to increase its vaccine manufacturing worldwide.
Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting.
Before becoming the global head of Johnson & Johnson External Innovation, William Hait spent 30 years in academic medicine focused on oncology. Whenever he speaks to a group, the first question he asks is if there is anyone in the room that would like to get a disease.
The number of biopharmas and nonprofits pitching in to find a treatment for COVID-19 continues to grow. In the past few weeks, that number has more than doubled and it shows no signing of slowing.
The number of biopharmas and nonprofits pitching in to find a treatment for COVID-19 continues to grow. In the past few weeks, that number has more than doubled and it shows no signing of slowing.
Intuitive Surgical Inc. more than gave back all its 2020 share price gains thus far, dipping almost 4% on earnings news. Over the past few years, its valuation (NASDAQ:ISRG) repeatedly has climbed, only to later retrench and then rise again to a slightly higher peak.
Israeli startup Zebra Medical Vision Ltd. has partnered with Johnson & Johnson’s Depuy Synthes to develop artificial intelligence (AI)-based algorithms to reduce the costs and radiation risks associated with imaging to prepare for orthopedic surgery.
Significant progress is being made in the development of next-generation treatments for multiple myeloma. For that reason, investors and industry analysts alike will be anxiously awaiting the abstracts for the upcoming American Society of Hematology (ASH) annual meeting.
